<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Egypt Heart J</journal-id><journal-id journal-id-type="iso-abbrev">Egypt Heart J</journal-id><journal-title-group><journal-title>The Egyptian Heart Journal</journal-title></journal-title-group><issn pub-type="ppub">1110-2608</issn><issn pub-type="epub">2090-911X</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407974</article-id><article-id pub-id-type="pmc">PMC12102026</article-id>
<article-id pub-id-type="publisher-id">644</article-id><article-id pub-id-type="doi">10.1186/s43044-025-00644-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeted delivery of peptide functionalized nanoparticles for ameliorating myocardial infarction</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abhirami</surname><given-names>N</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sudhina</surname><given-names>S</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Chandran</surname><given-names>Akash</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Chandran</surname><given-names>Mahesh</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8074-3709</contrib-id><name><surname>Ayyappan</surname><given-names>Janeesh Plakkal</given-names></name><address><email>janeeshbiochemistry@keralauniversity.ac.in</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tqa9940</institution-id><institution-id institution-id-type="GRID">grid.413002.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 5111</institution-id><institution>Translational Nanomedicine and Lifestyle Disease Research Laboratory, Department of Biochemistry, </institution><institution>University of Kerala, </institution></institution-wrap>Kariavattom Campus, Thiruvananthapuram, Kerala 695034 India </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tqa9940</institution-id><institution-id institution-id-type="GRID">grid.413002.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 5111</institution-id><institution>Centre for Advanced Cancer Research, Department of Biochemistry, </institution><institution>University of Kerala, </institution></institution-wrap>Kariavattom Campus, Thiruvananthapuram, Kerala 695034 India </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tqa9940</institution-id><institution-id institution-id-type="GRID">grid.413002.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 5111</institution-id><institution>Department of Nanoscience and Nanotechnology, </institution><institution>University of Kerala, </institution></institution-wrap>Kariavattom, Thiruvananthapuram, Kerala 695581 India </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05tqa9940</institution-id><institution-id institution-id-type="GRID">grid.413002.4</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 5111</institution-id><institution>Department of Biotechnology, </institution><institution>University of Kerala, </institution></institution-wrap>Kariavattom, Thiruvananthapuram, Kerala 695581 India </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>77</volume><elocation-id>48</elocation-id><history><date date-type="received"><day>27</day><month>6</month><year>2024</year></date><date date-type="accepted"><day>26</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Myocardial infarction (MI) continues to pose a significant global healthcare burden despite advances in treatment options and their effectiveness. The incidence, prevalence, and mortality rates associated with MI are rising, emphasizing the need for improved therapeutic strategies. Traditional invasive surgical methods, aimed at recanalizing blood flow to the coronary arteries, have proven insufficient in fully addressing the complexities of MI. This ongoing challenge necessitates the exploration of novel approaches to enhance treatment efficacy and outcomes for MI patients.</p></sec><sec><title>Main text</title><p id="Par2">One promising approach is the use of nanoparticle delivery systems for targeted therapy to the infarct site. When conventional methods fail to achieve adequate permeability and retention, nanoparticle strategies offer a potential solution. Functionalizing nanoparticles is a particularly effective technique, allowing these particles to conjugate with specific ligands. These ligands possess the intrinsic ability to selectively bind to receptors that are overexpressed or uniquely present at the infarct site, thereby conferring &#x0201c;smartness&#x0201d; to the nanoparticle constructs. This review delves into the various strategies employed in nanoparticle-ligand functionalization, highlighting the versatility and potential of these approaches. It provides a detailed cross section of several ligand classes, each with unique properties and binding affinities that make them suitable for targeted delivery in the context of MI. The focus is on identifying ligands that are either unique to the infarcted myocardium or significantly upregulated during MI, ensuring precise and efficient targeting of therapeutic agents.</p></sec><sec><title>Conclusion</title><p id="Par3">In summary, while traditional surgical methods for restoring blood flow in MI patients remain important, they are not sufficient on their own. By leveraging the specificity of these ligands, nanoparticles can be directed precisely to the infarct site, enhancing the delivery and efficacy of therapeutic agents. This review underscores the need for continued research into nanoparticle-ligand functionalization strategies, aiming to improve outcomes for MI patients and reduce the global burden of this condition.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Drug delivery system</kwd><kwd>MI therapeutics</kwd><kwd>Myocardial infarction</kwd><kwd>Nanoparticles</kwd><kwd>Targeted delivery</kwd><kwd>Surface modification</kwd></kwd-group><funding-group><award-group><funding-source><institution>Science and Engineering Research Board</institution></funding-source><award-id>SRG/2021/001831</award-id><principal-award-recipient><name><surname>Ayyappan</surname><given-names>Janeesh Plakkal</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>University Grants Commission (UGC)</institution></funding-source><award-id>F.30-596/2021(BSR)</award-id><principal-award-recipient><name><surname>Ayyappan</surname><given-names>Janeesh Plakkal</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Department of Science and Technology</institution></funding-source><award-id>DST/INSPIRE/03/2021/001574</award-id><principal-award-recipient><name><surname>Abhirami</surname><given-names>N</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>University of kerala</institution></funding-source><award-id>Plan</award-id><award-id>Non plan fund</award-id><principal-award-recipient><name><surname>Ayyappan</surname><given-names>Janeesh Plakkal</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Egyptian Society of Cardiology 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par4">According to the latest reports, coronary artery disease (CAD) is considered as the foremost cause of mortality, leading to millions of deaths each year [<xref ref-type="bibr" rid="CR1">1</xref>]. According to Scopus, there have been only 1702 papers published on the&#x000a0;application of nanotechnology to heart diseases in the last decade, which indicates that nanotechnology is in its infancy when it comes to cardiovascular pathology [<xref ref-type="bibr" rid="CR2">2</xref>]. Most of the drugs, currently available for&#x000a0;cardiovascular therapy fail to accumulate infarct tissue, resulting in minimal concentrations and ultimately causing damage to other tissues [<xref ref-type="bibr" rid="CR3">3</xref>]. Another major concern while dealing with MI is the negligible regeneration capacity of cardiomyocytes [<xref ref-type="bibr" rid="CR4">4</xref>]. The need for developing new regeneration techniques is highlighted by the fact that the sole therapeutic option for advanced disease conditions is organ transplantation, which is constrained due to donor shortages.</p><sec id="Sec2"><title>Main text</title><p id="Par5">MI is one of the most significant components of IHD, arising when blood flow to the myocardium is decreased or completely halted (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). An infarction can be silent and go undetected, or it can be catastrophic, resulting in hemodynamic deterioration and sudden death [<xref ref-type="bibr" rid="CR5">5</xref>]. MI may lead to several other complications such as heart failure, arrhythmia, cardiac arrest, or cardiogenic shock [<xref ref-type="bibr" rid="CR6">6</xref>]. In order to restore perfusion and avoid myocardial necrosis, the current treatments for MI mostly concentrate on recanalizing the blocked coronary artery and the&#x000a0;administration of medicines in high concentrations, which can be detrimental to other organs. Cardiac remodeling is usually followed by changes in the geometry and morphology of the myocytes. Hypertrophy and fibrosis of the left ventricular wall of the&#x000a0;heart usually occurr during the pathogenesis of MI. During this process, there will be an increased production of chemokine and cytokines that in turn mediates the macrophage activation to clear the cell and matrix debris. This triggers the expansion of fibroblasts and secrets a collagen-based matrix network. The adult mammalian heart has an abundance of interstitial and perivascular fibroblasts that grows and helps in repair the damage, but also leads to maladaptive fibrotic remodeling. After a MI, cardiac fibroblasts undergo continuous morphological modifications that assist in&#x000a0;governing inflammatory, restoration, and vascular responses. When the infarcted heart is repaired, the dead myocardium is eventually replaced by non-contractile collagen-based scar&#x000a0;tissue. Resident cardiac fibroblasts in the ischemic area develop a pro-inflammatory phenotype, recruit leukocytes via cytokine secretion, and transform into myofibroblasts during the inflammatory and proliferative phases, contributing to scar formation and maintenance in heart injury. (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Pathological processes involve increased ROS, altered extracellular matrix, cessation of oxidative phosphorylation, anaerobic glycolysis, mitochondrial swelling, plasmalemma breakage, subsarcolemmal bleb formation, severe mitochondrial swelling, disorganized cristae, and ultra-structural evidence of amorphous matrix densities</p></caption><graphic xlink:href="43044_2025_644_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Dynamic process of cardiac remodeling and fibrosis following a myocardial infarction (MI)</p></caption><graphic xlink:href="43044_2025_644_Fig2_HTML" id="MO2"/></fig></p><p id="Par6">Therefore, there is an urgent need to develop a drug delivery system (DDS) that target cardiovascular medications to the myocardium. DDSs are a category of nano-constructs that can encapsulate lipophilic as well as hydrophilic drugs thereby improving their durability and water-soluble nature, minimize their physiological clearance, and regulate their bio-distribution, inactivation, or degradation to optimize their safety and effectiveness. Because targeting means accurate accumulation of the drug in the infarct site with little impact on the neighboring healthy tissues, it is crucial for site-specific drug delivery [<xref ref-type="bibr" rid="CR7">7</xref>]. Therefore, nanotechnology improves tissue regeneration, imaging, and drug delivery in the treatment of MI. Targeted drug delivery is made possible by nanoparticles like PLGA-PEG, liposomes, and gold nanoparticles, which also improve bioavailability and lessen side effects. Iron oxide nanoparticles enhance infarct imaging, and stem cell-loaded nanoscaffolds aid in myocardial healing. Furthermore, oxidative stress is decreased by ROS-scavenging nanoparticles (like cerium oxide), which prevent additional cardiac damage. In this review, we will explore and outline potential strategies for targeting drugs to the myocardium using nanoparticles.</p></sec><sec id="Sec3"><title>Nanoparticles tagged with proteins of interest for drug delivery</title><p id="Par7">The majority of recent research has focused on creating nanocarriers as prospective DDSs. The size of nanoparticles, which ranges from 1 to 100 nanometers, is much smaller than that of biological macromolecules like protein and DNA. They have the ability to interact with biological systems and can overcome biological barriers easily. The application of nano-based delivery systems include increased efficacy, improved pharmacokinetics, bioavailability, increased medicinal effect, site-specific drug release, increased solubility, and are safe and secure (Fig. <xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Cell internalization by active targeting nanoparticles has been suggested to improve therapeutic efficacy in comparison with non-targeted nanoparticles because the targeting ligand&#x02019;s primary function is to enhance the uptake of nanoparticles into target cells. NPs promote pharmacokinetics, increased efficacy, safer and secure application, increased solubility, site-specific action and release, promote medicinal effect and boost bioavailability</p></caption><graphic xlink:href="43044_2025_644_Fig3_HTML" id="MO3"/></fig></p><p id="Par8">Nanocarriers are classified into organic and inorganic nanoparticles as well as hybrid groups [<xref ref-type="bibr" rid="CR8">8</xref>]. Sometime different combinations of these materials are also effective (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>Schematic representation of different types of nanoparticles (NPs) divided into organic, hybrid and inorganic categories. Organic nanoparticles include alginate nanoparticles, liposomes, solid lipid nanoparticles, hydrogels, and dendrimers. Inorganic nanoparticles include gold nanoparticles, silver nanoparticles, iron oxide, carbon nanotubes, and silica</p></caption><graphic xlink:href="43044_2025_644_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec4"><title>Organic nanoparticle</title><sec id="Sec5"><title>Liposomes</title><p id="Par9">Lipid nanoparticles represented by liposomes are composed of a phospholipid bilayer membrane, most of the time, they take the shape of a vesicle. It has been demonstrated that the proangiogenic cytokine vascular endothelial growth factor (VEGF) encourages neovascularization in heart disease patients [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Because VEGF plays a role in angiogenesis, its local distribution may have a major impact on the prognosis of MI by encouraging the development of neocapillaries, reducing local ischemia, and favoring the decrease in necrotic tissue. Clinical investigations have shown that therapeutic results can only be attained at high doses but not without side effects such as hypotension, retinopathy, and malignant tumor progression [<xref ref-type="bibr" rid="CR11">11</xref>]. In 2010, Oh et al. created nanoparticles with a core made of lecithin and VEGF, and a coating made of &#x0201c;poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) triblock copolymer&#x0201d; due to the short half-life, quick clearance, and requirement to maintain an optimal risk-benefit ratio of VEGF. The end product is delivered into the peri-necrotic area of the rat heart. The nanoparticle dramatically increased the quantity of capillaries in the necrotic zone with or without the gel, indicating that VEGF conjugation was effective. [<xref ref-type="bibr" rid="CR12">12</xref>] (Figure <xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>Conventional liposomes comprising phospholipids, a layer of polyethylene glycol (PEG)-specific ligand to target infarct site; which can be used for diagnosis and treatment</p></caption><graphic xlink:href="43044_2025_644_Fig5_HTML" id="MO5"/></fig></p><p id="Par10">Angiotensin II is an important component of the &#x0201c;renin-angiotensin-aldosterone pathway&#x0201d; and may be concentrated on by the nanoparticles to modulate cardiac remodeling [<xref ref-type="bibr" rid="CR13">13</xref>]. It is known that AT1 and AT2 are at least two different types of polypeptide receptors that mediate the activity of angiotensin II [<xref ref-type="bibr" rid="CR14">14</xref>]. The activity of AT1 receptors is enhanced in the heart during severe ischemia and after MI, and receptor-mediated endocytosis is used to internalize them when human serum albumin nanoparticles or functionalized liposomes are used to target them [<xref ref-type="bibr" rid="CR15">15</xref>]. In the early stages of cardiovascular diseases, activation of the above pathway is compensatory, but it gradually turns maladaptive. Studies show that angiotensin II type 1 (AT1) that contain (G-G-G-G-D-R-V-Y-I-H-P-F) amino acid sequence binds to the AT1 receptor present in cardiac cells. Nanoparticles targeting ATI receptor can be prepared by conjugating ATI targeting peptide to the COO- functional group on the liposomes. During cell culture studies, there was a threefold expansion in AT1 receptors in injured ventricular cardiomyocyte, and 83% of NPs found to be concentrated in these cells [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par11">Apelin 13 and apelin 36, ligands for the receptor apelin (APJ), promote coronary and peripheral vasodilation and aid in the maintenance of cardiac homeostasis. Apelin and APJ were either maintained or down-regulated in progressive hypertrophy of the left ventricle, or compensated cardiomyopathy, whereas their expression was decreased by the commencement of decompensation [<xref ref-type="bibr" rid="CR17">17</xref>]. Apelin administration has been shown to reduce ventricular hypertrophy and improve glucose intolerance [<xref ref-type="bibr" rid="CR18">18</xref>]. Using PEG-coated liposomes as nanocarriers for [Pyr1]-apelin-13, the insufficient cellular and <italic>in vivo</italic> stability of the multiple isoforms of apelin has been resolved, allowing for sustained release and minimizing muscular expansion and tissue fibrosis [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par12">Another important nanoparticulate is the oleate adenosine pro-drug lipid nano-construction with atrial natriuretic peptide (ANP). To produce enhanced stability and prolonged release, adenosine was conjugated to oleate acid. The selective targeting site can be made possible with the help of atrial natriuretic peptide (ANP) tag. It is an endogenous and potent hypotensive hormone, and is found to be elevated early after MI in the infarcted myocardium [<xref ref-type="bibr" rid="CR20">20</xref>]. ANP can be complexed with &#x0201c;Distearoylphosphatidylethanolaminated polyethylene glycol&#x0201d; (DSPE-PEG) to produce the nanoparticle transfer system. Adenosine oleate pro-drug can then be incorporated inside the core of ANP-PEG-DSPE, via the solvent evaporation method. <italic>In vitro</italic> experiments revealed rapid drug release and high intracellular absorption efficiency within 24 hours [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par13">Dual modified liposome carriers made of cholesterol, soybean phospholipids, and DSPE-PEG are widely used as the carrier for delivering drugs to myocardium. It consists of two targeting peptides, TAT, an 11-mer peptide (YGRKKRRQRRR), and PCM, a 20-mer peptide (WLSEAGPVVTVRALRGTGSW). High-affinity PCM binds only to cardiomyocytes, whereas TAT encourages intracellular penetration by non-specific endocytosis [<xref ref-type="bibr" rid="CR22">22</xref>].</p><p id="Par14">Recombinant tissue plasminogen (rtPA) was combined by Huang et al., with PEGylated liposomes coated with the cRGD peptide for precise and regulated drug administration [<xref ref-type="bibr" rid="CR23">23</xref>]. This membrane fusion facilitates interactions with activated platelet GPIIb/IIIa integrins and cRGD peptides on liposomes. Due to liposomal membrane destabilization, 90% of rtPA releases occured within 1 hour [<xref ref-type="bibr" rid="CR24">24</xref>].</p><p id="Par15">Pawlowski et al. developed a liposomal delivery system for each GPIIb/IIIa and P-selectin using the peptide sequences CDAEWVDVS and CGSSSGRGDSPA. The encapsulated medication is released as a result of leukocyte and active platelet breakdown by the secreted phospholipase A2 (sPLA2) enzyme [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p id="Par16">KO and his&#x000a0;group developed another multivalent targeting using anti-myosin monoclonal antibody (mAb 2G4) and TAT peptide. Cardiac myosin exposed to the extracellular surface is an indicator of MI. The receptors in ischemia cells may be recognized and bound by mAb 2GA [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par17">Following ischemia events, endothelial cells exhibit an increase in P-selectin expression. To treat rats with MI, Scott and colleagues created anti-P-selectin conjugated lipid nanocarriers. HSPC, cholesterol, and DSPE-PEG were used to create anti-P-selectin complexes to nanostructures by thiol group modifications. VEGF was further incorporated to the liposomes to increase their effectiveness in vascularizing the injured myocardium [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p></sec></sec><sec id="Sec6"><title>Solid lipid nanoparticles (SLNs)</title><p id="Par18">SLNs are lipid monolayer that surrounds a solid core that is stabilized by a surfactant. It is an alternate method of drug delivery with a greater incidence of drug entrapment for hydrophobic drugs. Dong et al. proposed another innovative solid lipid SLN system synthesis. This SLN is composed of two components: a PEG-DSPE modified with the RGD peptide, and a solid middle layer formed of a lipid excipient and soy lecithin. The v3 integrin, which is overexpressed in endothelial cells, binds to the RGD peptide. The fast drug release was noticed during the first 12 hours, and in vitro research demonstrates the buildup of RGD/PEG-PUE-SLN [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec7"><title>Polymeric nanoparticles</title><p id="Par19">One of the most efficient biodegradable copolymers is &#x0201c;poly (d, l-lactic acid), poly (d, l-glycolic acid&#x0201d; (PLGA), which is frequently utilized because of its low lethal impact, high sustainability, and biodegradability. PLGA NPs complexed with insulin-like growth factor-1 (IGF-1) provides early cardio-protection throughout the course of MI. IGF-1 has been proven to boost heart function after myocardial infarction and to induce cardiomyocyte growth. Electrostatic interaction between anionic IGF-1 and PLGA causes complexes to form&#x000a0;into a nanovehicle [<xref ref-type="bibr" rid="CR30">30</xref>]. Didodecyldimethylammonium bromide (DMAB) or PVA as a surfactant were used in the production of PLGA with 10 g rtPA because DMAB-stabilized NPs had a stronger affinity for fibrin clots [<xref ref-type="bibr" rid="CR31">31</xref>]. By inhibiting opsonization, surface PEGylation of PLGA NPs enhances biocompatibility and pharmacokinetics. rtPA was enclosed in a PLGA and Fe<sub>3</sub>O<sub>4</sub> shell, and a chitosan-cRGD peptide was grafted onto the surface to target GPIIb/IIIa [<xref ref-type="bibr" rid="CR32">32</xref>]. This nanovehicle is made up of brush peptide-polymer amphiphiles with functional groups specific for matrix metalloproteinase. Until they enter the injured site by vascular leakage, these structures are stable in blood circulation [<xref ref-type="bibr" rid="CR33">33</xref>]. The systemic targeting of thymosin beta 4 (T4), a 43 amino acid, to the infarcted myocardium by &#x0201c;cysteine-arginine-glutamic acid-lysine-alanine&#x0201d; (CREKA)-modified NPs was suggested to improve the therapeutic efficacy. T&#x003b2;4 promotes epicardial and coronary artery development and has been reported to be overexpressed in the infarcted heart. T&#x003b2;4 complements coronary heart functions by protecting the cardiomyocytes from apoptosis and by activating epicardial progenitor cells. Oduk et al. in 2018 loaded PLGA nanoparticles with VEGF with an average size of 113 nm.</p><p id="Par20">Chitosan, an ionic hydrophilic polysaccharide, interacts with molecules that are negatively charged to form polyelectrolyte aggregates [<xref ref-type="bibr" rid="CR34">34</xref>]. Ionic crosslinking with sodium tripolyphosphate can be used to create self-assembled chitosan NPs. Liao et al. covalently bonded trimethyl chitosan (TMC) with cRGD, allowing the nanoparticle to target GPIIb/IIIa receptors precisely [<xref ref-type="bibr" rid="CR35">35</xref>].</p></sec><sec id="Sec8"><title>Inorganic nanoparticles</title><p id="Par21">Another type of drug delivery technique is by the use of magnetic nanoparticles. Using an external high-gradient magnetic field, MNPs laden with fibrinolytic medicines can be concentrated at the thrombus [<xref ref-type="bibr" rid="CR36">36</xref>].</p><p id="Par22">Mesoporous silica nanocarriers (MSNs) are mostly used&#x000a0;for loading of large amount of fibrinolytic drugs via both active and passive targeting processes.</p><p id="Par23">Adenosine-loaded silica nanoparticles were fabricated by Galagudza and co-workers for the targeting of adenosine to the ischemic heart. When compared to free adenosine, it subsequently raises blood pressure and significantly shrinks the infarction size [<xref ref-type="bibr" rid="CR37">37</xref>]. Silica NPs loaded with a PED and ANP peptide for active medication can be delivered to the endocardia of wounded hearts. These NPs bind to the cardiomyocytes and non-myocytes via natriuretic peptide receptors that are overexpressed in the infarcted area.</p><p id="Par24">Due to multiple biological properties, including their outstanding biocompatibility, ability to easily be surface-modified with diverse functional groups, visible light extinction behavior, electrical, sensing, optical, and biochemical activities, gold nanoparticles are ideal drug carriers. Somasuntharam and co-workers synthesized 80-nm-sized gold NPs with deoxyribozyme (Dz) (Dz-AuNPs). Dz inhibits the activation of TNF-&#x003b1;. Dz-AuNPs have improved stability and cytocompatibility and can internalize in cardiomyocytes and macrophages. <italic>In vivo</italic> studies show that Dz-AuNPs reduce 50% of&#x000a0;TNF-&#x003b1; level&#x000a0;and other pro-inflammatory cytokines that trigger the oxidative stress [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>].</p><p id="Par25">Lately, graphene nanoparticles have shown potential as their reported bio-sensing applications have shown great diversity [<xref ref-type="bibr" rid="CR40">40</xref>]. It consists of ultra-high surface area due to the exposure of atoms on its surface. Functionalized graphene oxide (fGO) nanosheets are impregnated with methacrylated gelatin hydrogel (GelMA) conjugated with proangiogenic human VEGF plasmid DNA that are found to efficiently transfect the heart tissue, inducing favorable effects without producing cytotoxic consequences [<xref ref-type="bibr" rid="CR41">41</xref>]</p></sec><sec id="Sec9"><title>Chemistry of nanoparticle conjugation</title><p id="Par26">Chemistry of nanoparticle conjugation is shown in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Chemistry of nanoparticle conjugation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Type of Conjugation</th><th align="left">Linkage</th><th align="left">Stability</th><th align="left">Diagram</th></tr></thead><tbody><tr><td align="left">Electrostatic force</td><td align="left">Ionic interaction</td><td align="left">Stable</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Figa_HTML.gif" id="d33e507"/></td></tr><tr><td align="left">NH2/COOH</td><td align="left">Amide bond</td><td align="left">Stable</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Figb_HTML.gif" id="d33e518"/></td></tr><tr><td align="left">Thiol/Maleimide</td><td align="left">Thioether bond</td><td align="left">Stable</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Figc_HTML.gif" id="d33e529"/></td></tr><tr><td align="left">Thiol/Thiol</td><td align="left">Disulfide bond</td><td align="left">Cleaved under reducing condition</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Figd_HTML.gif" id="d33e540"/></td></tr><tr><td align="left">Hydrazide/Aldehyde</td><td align="left">Hydrazone</td><td align="left">Acid labile</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Fige_HTML.gif" id="d33e551"/></td></tr><tr><td align="left">Click Chemistry, i.e., Azide/Alkyne</td><td align="left">Triazole ring</td><td align="left">Stable</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Figf_HTML.gif" id="d33e562"/></td></tr><tr><td align="left">Biotin/(Strept) avidin</td><td align="left">Non- covalent Almost irreversible</td><td align="left">Stable</td><td align="left"><inline-graphic xlink:href="43044_2025_644_Figg_HTML.gif" id="d33e573"/></td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Physical adsorption</title><p id="Par27">Physical adsorption, which primarily depends on attractive forces such as hydrogen bonds, hydrophobic, van der Waals forces, and ionic interactions, is one of the basic coupling strategies [<xref ref-type="bibr" rid="CR42">42</xref>]. Tanaka et al. established the physical adsorption of monoclonal antibodies to the outermost layer of GNPs, which have the ability to bind antibodies to chorionic gonadotropin and the subunit of human follicle stimulating hormone (HFSH) without the requirement for any pre-modification treatments. Enhanced detection was performed with a sensitivity that was approximately 1000 times higher than the traditional detection method [<xref ref-type="bibr" rid="CR43">43</xref>]. Another method of producing gold nanoparticles by physical interactions that were coupled with immunoglobulin G (IgG) and anti-epidermal growth factor receptor (anti-EGFR) enhanced the activity of the&#x000a0;ligand. By minimizing the isoelectric point of IgG, they synthesized bio-conjugates that were irreversible and incredibly stable [<xref ref-type="bibr" rid="CR44">44</xref>]. Nanoparticle-bound antibodies are released by very slight pH shifts [<xref ref-type="bibr" rid="CR45">45</xref>].</p></sec><sec id="Sec11"><title>Covalent conjugation of nanoparticles</title><p id="Par28">Covalent conjugation chemistries are the most often utilized methods for modifying nanoparticles. These covalent conjugations involve active carbonyl groups. The reactions include the formation of an oxime bond when a carbonyl reacts with an alkoxyamine, or a hydrazone bond when it reacts with a hydrazide; the formation of an amide or amidine bond when a reactive amine group reacts with an activated carboxylate or an imidoester; and the formation of an amide bond or triazole ring when a reactive sulfhydryl group reacts with an azide and phosphine or an alkyne.</p></sec><sec id="Sec12"><title>Amine-Carboxyl linkage</title><p id="Par29">An established method for conjugating antibodies to the surfaces of NPs is the carbodiimide coupling method [<xref ref-type="bibr" rid="CR46">46</xref>]. During this process, the carboxyl residues on the NPs&#x02019; surface are activated, allowing them to covalently link with the -NH group of the antibodies. Despite the fact that carboxyl moieties do not naturally attach to antibodies, they can be chemically altered to do so. In the bio-conjugation technique, reactive groups like hydroxyl and amine moieties which may chemically link with the amino acids side chains on the outermost layer of the antibody are added to the nanoparticles&#x02019; surfaces. This method can be done using identified bio-conjugation techniques such as EDC/NHS, which results in the formation of reactive NHS esters. When EDC reacts with a carboxylic group, the intermediate product O-acylisourea ester is transformed into its active form. When it interacts with a&#x000a0;primary amine, the latter produces an amide bond. For polymers having reactive carboxyl groups in their side chains, this method is highly practical [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The DSPE-PEG-COOH system was used, and it served as the supply of the necessary carboxylic acid groups.</p></sec><sec id="Sec13"><title>Hydrazide-Aldehyde linkage</title><p id="Par30">To undergo hydrazine bio-conjugation, a molecule must have a carbonyl moiety or an alpha nucleophile present, which will undergo a simple reaction to form hydrazones under mildly acidic conditions. Typically, hydrazine bio-conjugation chemistry involves the&#x000a0;reaction of the NH group of the amine with aldehydes and ketones on biomolecules to form an imine. A covalent hydrazone link can be created when the aldehyde group directly reacts with the hydrazide through a nucleophilic addition [<xref ref-type="bibr" rid="CR49">49</xref>]. The residual aldehyde group found in antibodies&#x02019; Fc domains has significant reactivity with substrate surfaces triggered by hydrazides, making it a possible replacement for site-specific directed coupling. Selective bio-conjugation reaction of NP-hydrazide to aldehyde-containing antibodies involves mild periodate oxidation of&#x000a0;the antibody, synthesis of NP-hydrazide via derivatization of NP-COOH with EDC/ADH; and conjugation of NP-hydrazide with antibody-CHO via formation of hydrazone linkage.</p></sec><sec id="Sec14"><title>Thiol-Maleimide linkage</title><p id="Par31">This method uses the sulfhydryl (-SH) groups of antibodies. The -SH groups on antibodies are formed by interacting with primary amines or breaking their original disulfide bonds. Additionally, this chemical group is easily generated by using sulfhydryl-addition chemicals to modify the lysine residues&#x02019; amino. The most popular one is the Traut&#x02019;s reagent [<xref ref-type="bibr" rid="CR50">50</xref>]. At neutral pH, maleimide groups react with free sulfhydryls 1000 times quicker than they do with primary amines, increasing selectivity. Following the&#x000a0;alkylation reaction with sulfhydryl groups, a thioether bond is created. &#x0201c;Sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), and NHS/maleimide heterobifunctional linkers&#x0201d; are the widely used maleimide crosslinking agents [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR54">54</xref>]. The free thiol group is used to conjugate antibodies to the carrier.</p></sec><sec id="Sec15"><title>Thiol-Thiol linkage</title><p id="Par32">Conjugation of a primary and secondary thiol group forms the disulfide bond in thiol-thiol linkage. The primary group is derived from a nanocarrier, while the secondary group is derived from a ligand. Thiol groups of a ligand can be formed by reducing disulfide functionalities or by using appropriate agents such&#x000a0;as SATA or SPDP [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>].</p></sec><sec id="Sec16"><title>Click chemistry linkage</title><p id="Par33">High efficiency, stereospecificity, and safe by-products are characteristics of reactions of the &#x0201c;click chemistry&#x0201d; group. Maleimide-thiol conjugation or EDC/NHS coupling are the two processes used to functionalize NPs with azide or alkyne moieties. The Huisgen cycloaddition is the most common kind of &#x0201c;click chemistry&#x0201d; reaction. When azides and terminal alkynes undergo 1,3-dipolar cycloaddition using catalyst Cu (I), 1,2,3-triazole is produced. Huisgen&#x02019;s cycloaddition demands the use of reagents that can tolerate biological molecules and aqueous solutions with a wide range of pH levels [<xref ref-type="bibr" rid="CR57">57</xref>]. Hassane et al. described the efficient liposome-ligand conjugation focused on Huisgen&#x02019;s cycloaddition [<xref ref-type="bibr" rid="CR58">58</xref>]. The ligand was an azide-group-containing derivative of D-mannose.</p></sec><sec id="Sec17"><title>Antibody-conjugated nanoparticle using adaptor biomolecules</title><p id="Par34">Streptavidin, avidin, NeutrAvidin, and other molecules can be conjugated to biotin to create extremely stable complexes that can embrace a variety of chemical, pH, and temperature conditions [<xref ref-type="bibr" rid="CR59">59</xref>]. In order to create antibody conjugates, the antibody&#x000a0;is modified with biotin and then couples with avidin-modified nanoparticles through non-covalent interactions [<xref ref-type="bibr" rid="CR60">60</xref>]. Avidin is a glycoprotein with a high pI, but it also tends to aggregate and bind to substances other than biotin, which reduces the specificity of the conjugate and makes it less promising than streptavidin&#x02013;biotin interactions [<xref ref-type="bibr" rid="CR61">61</xref>]. Steric factors are unlikely to prevent the coupling from occurring since each streptavidin monomer has as many as four sites for biotin binding [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>]. Avidin-fatty acid conjugates were employed in one investigation by Fahmy et al. to incorporate the targeted ligands. Avidin was guided into the aqueous environment using polar fatty acids (palmitic acid) to improve association with the antibodies. This coupling approach is more stable and may be employed with polymers such as PLGA, which only have a few functional chemical groups accessible for conjugation. Additionally, the increased avidin incorporation density on the particles may lead to better protein production and encapsulation when compared to unmodified particles. Furthermore, Park et al. investigated how various fatty acids affected avidin&#x02019;s ability to integrate nanoparticles.</p></sec></sec><sec id="Sec18"><title>Conclusion</title><p id="Par35">This review&#x02019;s main objective is to demonstrate how readily the notion of targeted drug delivery using nanostructured materials may be applied to coronary artery disorders, in addition to providing an overview of how easily this concept can be applied to coronary artery diseases. Nanotechnology-based drug delivery systems are currently in&#x000a0;a pivotal stage of preclinical trial and scientific trial. They show tremendous effects in&#x000a0;the diagnosis and treatment of MI. The aim of this review is to put forward an appropriate idea on nanocarriers fabricated for drug delivery and their targeting sites. Newly found nanostructures may be crucial in the development of an advanced MI diagnosis and therapy in the future. The demanding situations in gene delivery like cellular uptake and pharmacokinetics could be overcome via the usage of appropriate nanocarriers.</p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The author expresses gratitude to the Department of Science &#x00026; Technology for the Innovation in Science Pursuit for Inspired Research (INSPIRE) grant, the Science and Engineering Research Board (SERB), India, for the Start-up Research Grant, the University Grants Commission (UGC), India, for the Start-up grant for new faculty, and the University of Kerala for research support through Plan and Nonplan funds. The figures in this article were created using BioRender.com.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conceptualization was done by J. P. A. and A.N.; methodology was done by A.N.; literature collection was done by A.N, S. S., A.C., and M. C.; data curation and writing of original draft were done by A.N.; and reviewing, editing, and finalizing the manuscript were done by J. P. A. and A. N.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Department of Science &#x00026; Technology for the Innovation in Science Pursuit for Inspired Research (INSPIRE) grant, the Science and Engineering Research Board (SERB), India, for the Start-up Research Grant, the University Grants Commission (UGC), India, for the Start-up grant for new faculty, and the University of Kerala for research support through Plan and Nonplan funds.</p></notes><notes><title>Declarations</title><notes><title>Availability of data and materials</title><p>Not applicable.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interest</title><p id="Par36">The authors declare that they have no competing interests.</p></notes><notes id="FPar2"><title>Ethics approval and consent to participate</title><p id="Par37">Not applicable</p></notes><notes id="FPar3"><title>Consent for publication</title><p>Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Nowbar</surname><given-names>AN</given-names></name><name><surname>Gitto</surname><given-names>M</given-names></name><name><surname>Howard</surname><given-names>JP</given-names></name><name><surname>Francis</surname><given-names>DP</given-names></name><name><surname>Al-Lamee</surname><given-names>R</given-names></name></person-group><article-title>Mortality from ischemic heart disease: analysis of data from the world health organization and coronary artery disease risk factors from NCD risk factor collaboration</article-title><source>Circ: Cardiovasc Quality Outcomes</source><year>2019</year><volume>12</volume><issue>6</issue><fpage>005375</fpage><pub-id pub-id-type="doi">10.1161/CIRCOUTCOMES.118.005375</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Nowbar AN, Gitto M, Howard JP, Francis DP, Al-Lamee R (2019) Mortality from ischemic heart disease: analysis of data from the world health organization and coronary artery disease risk factors from NCD risk factor collaboration. Circ: Cardiovasc Quality Outcomes 12(6):005375. 10.1161/CIRCOUTCOMES.118.005375</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonciar</surname><given-names>D</given-names></name><name><surname>Mocan</surname><given-names>T</given-names></name><name><surname>Agoston-Coldea</surname><given-names>L</given-names></name></person-group><article-title>Nanoparticles targeting the molecular pathways of heart remodeling and regeneration</article-title><source>Pharmaceutics</source><year>2022</year><volume>14</volume><issue>4</issue><fpage>711</fpage><pub-id pub-id-type="doi">10.3390/pharmaceutics14040711</pub-id><pub-id pub-id-type="pmid">35456545</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Gonciar D, Mocan T, Agoston-Coldea L (2022) Nanoparticles targeting the molecular pathways of heart remodeling and regeneration. Pharmaceutics 14(4):711. 10.3390/pharmaceutics14040711<pub-id pub-id-type="pmid">35456545</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Lestini</surname><given-names>BJ</given-names></name><name><surname>Sagnella</surname><given-names>SM</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery</article-title><source>J Control Release</source><year>2002</year><volume>78</volume><issue>1&#x02013;3</issue><fpage>235</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/s0168-3659(01)00505-3</pub-id><pub-id pub-id-type="pmid">11772464</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Lestini BJ, Sagnella SM, Xu Z et al (2002) Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J Control Release 78(1&#x02013;3):235&#x02013;247. 10.1016/s0168-3659(01)00505-3<pub-id pub-id-type="pmid">11772464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>G</given-names></name><name><surname>Di Benedetto</surname><given-names>G</given-names></name><name><surname>Passaro</surname><given-names>F</given-names></name></person-group><article-title>Advanced technologies to target cardiac cell fate plasticity for heart regeneration</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>17</issue><fpage>9517</fpage><pub-id pub-id-type="doi">10.3390/ijms22179517</pub-id><pub-id pub-id-type="pmid">34502423</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Testa G, Di Benedetto G, Passaro F (2021) Advanced technologies to target cardiac cell fate plasticity for heart regeneration. Int J Mol Sci 22(17):9517. 10.3390/ijms22179517<pub-id pub-id-type="pmid">34502423</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Thygesen</surname><given-names>K</given-names></name><name><surname>Alpert</surname><given-names>JS</given-names></name><name><surname>White</surname><given-names>HD</given-names></name></person-group><article-title>Force for the redefinition of myocardial infarction</article-title><source>Circulation</source><year>2007</year><volume>116</volume><fpage>2634</fpage><lpage>2653</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.187397</pub-id><pub-id pub-id-type="pmid">17951284</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Thygesen K, Alpert JS, White HD (2007) Force for the redefinition of myocardial infarction. Circulation 116:2634&#x02013;2653<pub-id pub-id-type="pmid">17951284</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Lewis</surname><given-names>EF</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Jablonski</surname><given-names>KA</given-names></name></person-group><article-title>Predictors of heart failure in patients with stable coronary artery disease: a PEACE study Circ</article-title><source>Heart Fail</source><year>2009</year><volume>2</volume><fpage>209</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.108.820696</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Lewis EF, Solomon SD, Jablonski KA (2009) Predictors of heart failure in patients with stable coronary artery disease: a PEACE study Circ. Heart Fail 2:209&#x02013;216</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Sarkar</surname><given-names>A</given-names></name><etal/></person-group><article-title>Nanoparticle based treatment for cardiovascular diseases</article-title><source>Cardiovasc Hematol Disord Drug Targets</source><year>2019</year><volume>19</volume><issue>1</issue><fpage>33</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.2174/1871529x18666180508113253</pub-id><pub-id pub-id-type="pmid">29737265</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Gupta P, Garcia E, Sarkar A et al (2019) Nanoparticle based treatment for cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets 19(1):33&#x02013;44. 10.2174/1871529x18666180508113253<pub-id pub-id-type="pmid">29737265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>AZ</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Biofunctionalized targeted nanoparticles for therapeutic applications</article-title><source>Expert Opin Biol Ther</source><year>2008</year><volume>8</volume><issue>8</issue><fpage>1063</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1517/14712598.8.8.1063</pub-id><pub-id pub-id-type="pmid">18613759</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Wang AZ, Gu F, Zhang L et al (2008) Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 8(8):1063&#x02013;1070. 10.1517/14712598.8.8.1063<pub-id pub-id-type="pmid">18613759</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Oduk</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Kannappan</surname><given-names>R</given-names></name><etal/></person-group><article-title>VEGF nanoparticles repair the heart after myocardial infarction</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2018</year><volume>314</volume><issue>2</issue><fpage>H278</fpage><lpage>H284</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00471.2017</pub-id><pub-id pub-id-type="pmid">29101176</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Oduk Y, Zhu W, Kannappan R et al (2018) VEGF nanoparticles repair the heart after myocardial infarction. Am J Physiol Heart Circ Physiol 314(2):H278&#x02013;H284. 10.1152/ajpheart.00471.2017<pub-id pub-id-type="pmid">29101176</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Kivel&#x000e4;</surname><given-names>R</given-names></name><name><surname>Hemanthakumar</surname><given-names>KA</given-names></name><name><surname>Vaparanta</surname><given-names>K</given-names></name><etal/></person-group><article-title>Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling</article-title><source>Circulation</source><year>2019</year><volume>139</volume><issue>22</issue><fpage>2570</fpage><lpage>2584</lpage><pub-id pub-id-type="doi">10.1161/circulationaha.118.036099</pub-id><pub-id pub-id-type="pmid">30922063</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Kivel&#x000e4; R, Hemanthakumar KA, Vaparanta K et al (2019) Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-mediated paracrine signaling. Circulation 139(22):2570&#x02013;2584. 10.1161/circulationaha.118.036099<pub-id pub-id-type="pmid">30922063</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Golub</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>YT</given-names></name><name><surname>Duvall</surname><given-names>CL</given-names></name><etal/></person-group><article-title>Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2010</year><volume>298</volume><issue>6</issue><fpage>H1959</fpage><lpage>H1965</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.00199.2009</pub-id><pub-id pub-id-type="pmid">20228260</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Golub JS, Kim YT, Duvall CL et al (2010) Sustained VEGF delivery via PLGA nanoparticles promotes vascular growth. Am J Physiol Heart Circ Physiol 298(6):H1959&#x02013;H1965. 10.1152/ajpheart.00199.2009<pub-id pub-id-type="pmid">20228260</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>KS</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Yoon</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Yuk</surname><given-names>SH</given-names></name></person-group><article-title>Temperature-induced gel formation of core/shell nanoparticles for the regeneration of ischemic heart</article-title><source>J Control Release</source><year>2010</year><volume>146</volume><issue>2</issue><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.04.014</pub-id><pub-id pub-id-type="pmid">20417673</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Oh KS, Song JY, Yoon SJ, Park Y, Kim D, Yuk SH (2010) Temperature-induced gel formation of core/shell nanoparticles for the regeneration of ischemic heart. J Control Release 146(2):207&#x02013;211. 10.1016/j.jconrel.2010.04.014<pub-id pub-id-type="pmid">20417673</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Flores-Munoz</surname><given-names>M</given-names></name><name><surname>Work</surname><given-names>LM</given-names></name><name><surname>Douglas</surname><given-names>K</given-names></name><etal/></person-group><article-title>Angiotensin-(1&#x02013;9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor</article-title><source>Hypertension</source><year>2012</year><volume>59</volume><issue>2</issue><fpage>300</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1161/hypertensionaha.111.177485</pub-id><pub-id pub-id-type="pmid">22184331</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Flores-Munoz M, Work LM, Douglas K et al (2012) Angiotensin-(1&#x02013;9) attenuates cardiac fibrosis in the stroke-prone spontaneously hypertensive rat via the angiotensin type 2 receptor. Hypertension 59(2):300&#x02013;307. 10.1161/hypertensionaha.111.177485<pub-id pub-id-type="pmid">22184331</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Kaschina</surname><given-names>E</given-names></name><name><surname>Unger</surname><given-names>T</given-names></name></person-group><article-title>Angiotensin AT1/AT2 receptors: regulation, signalling and function</article-title><source>Blood Press</source><year>2003</year><volume>12</volume><issue>2</issue><fpage>70</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1080/08037050310001057</pub-id><pub-id pub-id-type="pmid">12797627</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kaschina E, Unger T (2003) Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press 12(2):70&#x02013;88. 10.1080/08037050310001057<pub-id pub-id-type="pmid">12797627</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Rivard</surname><given-names>K</given-names></name><name><surname>Grandy</surname><given-names>SA</given-names></name><name><surname>Douillette</surname><given-names>A</given-names></name><etal/></person-group><article-title>Overexpression of type 1 angiotensin II receptors impairs excitation-contraction coupling in the mouse heart</article-title><source>Am J Physiol Heart Circ Physiol</source><year>2011</year><volume>301</volume><issue>5</issue><fpage>H2018</fpage><lpage>H2027</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.01092.2010</pub-id><pub-id pub-id-type="pmid">21856918</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Rivard K, Grandy SA, Douillette A et al (2011) Overexpression of type 1 angiotensin II receptors impairs excitation-contraction coupling in the mouse heart. Am J Physiol Heart Circ Physiol 301(5):H2018&#x02013;H2027. 10.1152/ajpheart.01092.2010<pub-id pub-id-type="pmid">21856918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>C</given-names></name><name><surname>Cabigas</surname><given-names>EB</given-names></name><etal/></person-group><article-title>Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction</article-title><source>Biomaterials</source><year>2013</year><volume>34</volume><issue>14</issue><fpage>3729</fpage><lpage>3736</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.02.008</pub-id><pub-id pub-id-type="pmid">23433774</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Liu J, Gu C, Cabigas EB et al (2013) Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials 34(14):3729&#x02013;3736. 10.1016/j.biomaterials.2013.02.008<pub-id pub-id-type="pmid">23433774</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Japp</surname><given-names>AG</given-names></name><name><surname>Newby</surname><given-names>DE</given-names></name></person-group><article-title>The apelin&#x02013;APJ system in heart failure</article-title><source>Biochem Pharmacol</source><year>2008</year><volume>75</volume><issue>10</issue><fpage>1882</fpage><lpage>1892</lpage><pub-id pub-id-type="doi">10.1016/j.bcp.2007.12.015</pub-id><pub-id pub-id-type="pmid">18272138</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Japp AG, Newby DE (2008) The apelin&#x02013;APJ system in heart failure. Biochem Pharmacol 75(10):1882&#x02013;1892. 10.1016/j.bcp.2007.12.015<pub-id pub-id-type="pmid">18272138</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Ceylan-Isik</surname><given-names>AF</given-names></name><name><surname>Kandadi</surname><given-names>MR</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction</article-title><source>J Mol Cell Cardiol</source><year>2013</year><volume>63</volume><fpage>4</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.07.002</pub-id><pub-id pub-id-type="pmid">23859766</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Ceylan-Isik AF, Kandadi MR, Xu X et al (2013) Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 63:4&#x02013;13. 10.1016/j.yjmcc.2013.07.002<pub-id pub-id-type="pmid">23859766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Serpooshan</surname><given-names>V</given-names></name><name><surname>Sivanesan</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name></person-group><article-title>Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction</article-title><source>Biomaterials</source><year>2015</year><volume>37</volume><fpage>289</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.08.045</pub-id><pub-id pub-id-type="pmid">25443792</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Serpooshan V, Sivanesan S, Huang X (2015) Pyr1]-Apelin-13 delivery via nano-liposomal encapsulation attenuates pressure overload-induced cardiac dysfunction. Biomaterials 37:289&#x02013;298<pub-id pub-id-type="pmid">25443792</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Cannone</surname><given-names>V</given-names></name><name><surname>Cabassi</surname><given-names>A</given-names></name><name><surname>Volpi</surname><given-names>R</given-names></name><name><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group><article-title>Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><issue>13</issue><fpage>3265</fpage><pub-id pub-id-type="doi">10.3390/ijms20133265</pub-id><pub-id pub-id-type="pmid">31269783</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Cannone V, Cabassi A, Volpi R, Burnett JC Jr (2019) Atrial natriuretic peptide: a molecular target of novel therapeutic approaches to cardio-metabolic disease. Int J Mol Sci 20(13):3265. 10.3390/ijms20133265<pub-id pub-id-type="pmid">31269783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name></person-group><article-title>Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation</article-title><source>Drug Des Devel Ther</source><year>2018</year><volume>12</volume><fpage>1697</fpage><lpage>1706</lpage><pub-id pub-id-type="doi">10.2147/dddt.s166749</pub-id><pub-id pub-id-type="pmid">29928113</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Yu J, Li W, Yu D (2018) Atrial natriuretic peptide modified oleate adenosine prodrug lipid nanocarriers for the treatment of myocardial infarction: in vitro and in vivo evaluation. Drug Des Devel Ther 12:1697&#x02013;1706. 10.2147/dddt.s166749<pub-id pub-id-type="pmid">29928113</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name></person-group><article-title>PCM and TAT co-modified liposome with improved myocardium delivery: in vitro and in vivo evaluations</article-title><source>Drug Deliv</source><year>2017</year><volume>24</volume><issue>1</issue><fpage>339</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1080/10717544.2016.1253121</pub-id><pub-id pub-id-type="pmid">28165817</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Wang X, Huang H, Zhang L, Bai Y, Chen H (2017) PCM and TAT co-modified liposome with improved myocardium delivery: in vitro and in vivo evaluations. Drug Deliv 24(1):339&#x02013;345. 10.1080/10717544.2016.1253121<pub-id pub-id-type="pmid">28165817</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>J</given-names></name><etal/></person-group><article-title>An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy</article-title><source>J Control Release</source><year>2019</year><volume>300</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.02.033</pub-id><pub-id pub-id-type="pmid">30807804</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Huang Y, Yu L, Ren J et al (2019) An activated-platelet-sensitive nanocarrier enables targeted delivery of tissue plasminogen activator for effective thrombolytic therapy. J Control Release 300:1&#x02013;12. 10.1016/j.jconrel.2019.02.033<pub-id pub-id-type="pmid">30807804</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><etal/></person-group><article-title>Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis</article-title><source>Acta Biomater</source><year>2018</year><volume>70</volume><fpage>227</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2018.01.038</pub-id><pub-id pub-id-type="pmid">29412186</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhang N, Li C, Zhou D et al (2018) Cyclic RGD functionalized liposomes encapsulating urokinase for thrombolysis. Acta Biomater 70:227&#x02013;236. 10.1016/j.actbio.2018.01.038<pub-id pub-id-type="pmid">29412186</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Pawlowski</surname><given-names>CL</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><etal/></person-group><article-title>Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis</article-title><source>Biomaterials</source><year>2017</year><volume>128</volume><fpage>94</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2017.03.012</pub-id><pub-id pub-id-type="pmid">28314136</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pawlowski CL, Li W, Sun M et al (2017) Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis. Biomaterials 128:94&#x02013;108. 10.1016/j.biomaterials.2017.03.012<pub-id pub-id-type="pmid">28314136</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>YT</given-names></name><name><surname>Hartner</surname><given-names>WC</given-names></name><name><surname>Kale</surname><given-names>A</given-names></name><name><surname>Torchilin</surname><given-names>VP</given-names></name></person-group><article-title>Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide</article-title><source>Gene Ther</source><year>2009</year><volume>16</volume><issue>1</issue><fpage>52</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1038/gt.2008.135</pub-id><pub-id pub-id-type="pmid">18701915</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ko YT, Hartner WC, Kale A, Torchilin VP (2009) Gene delivery into ischemic myocardium by double-targeted lipoplexes with anti-myosin antibody and TAT peptide. Gene Ther 16(1):52&#x02013;59. 10.1038/gt.2008.135<pub-id pub-id-type="pmid">18701915</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RC</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Nallamothu</surname><given-names>R</given-names></name><etal/></person-group><article-title>Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction</article-title><source>Biotechnol Bioeng</source><year>2007</year><volume>96</volume><issue>4</issue><fpage>795</fpage><lpage>802</lpage><pub-id pub-id-type="doi">10.1002/bit.21233</pub-id><pub-id pub-id-type="pmid">17051598</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Scott RC, Wang B, Nallamothu R et al (2007) Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 96(4):795&#x02013;802. 10.1002/bit.21233<pub-id pub-id-type="pmid">17051598</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RC</given-names></name><name><surname>Rosano</surname><given-names>JM</given-names></name><name><surname>Ivanov</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function</article-title><source>FASEB J</source><year>2009</year><volume>23</volume><issue>10</issue><fpage>3361</fpage><lpage>3367</lpage><pub-id pub-id-type="doi">10.1096/fj.08-127373</pub-id><pub-id pub-id-type="pmid">19535683</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Scott RC, Rosano JM, Ivanov Z et al (2009) Targeting VEGF-encapsulated immunoliposomes to MI heart improves vascularity and cardiac function. FASEB J 23(10):3361&#x02013;3367. 10.1096/fj.08-127373<pub-id pub-id-type="pmid">19535683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Duong</surname><given-names>VA</given-names></name><name><surname>Nguyen</surname><given-names>TTL</given-names></name><name><surname>Maeng</surname><given-names>HJ</given-names></name></person-group><article-title>Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method</article-title><source>Molecules</source><year>2020</year><volume>25</volume><issue>20</issue><fpage>4781</fpage><pub-id pub-id-type="doi">10.3390/molecules25204781</pub-id><pub-id pub-id-type="pmid">33081021</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Duong VA, Nguyen TTL, Maeng HJ (2020) Preparation of solid lipid nanoparticles and nanostructured lipid carriers for drug delivery and the effects of preparation parameters of solvent injection method. Molecules 25(20):4781. 10.3390/molecules25204781<pub-id pub-id-type="pmid">33081021</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MY</given-names></name><name><surname>Yang</surname><given-names>YJ</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction</article-title><source>J Control Release</source><year>2013</year><volume>170</volume><issue>2</issue><fpage>287</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2013.04.022</pub-id><pub-id pub-id-type="pmid">23665256</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Chang MY, Yang YJ, Chang CH et al (2013) Functionalized nanoparticles provide early cardioprotection after acute myocardial infarction. J Control Release 170(2):287&#x02013;294. 10.1016/j.jconrel.2013.04.022<pub-id pub-id-type="pmid">23665256</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Sivaraman</surname><given-names>B</given-names></name><name><surname>Sylvester</surname><given-names>A</given-names></name><name><surname>Ramamurthi</surname><given-names>A</given-names></name></person-group><article-title>Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix</article-title><source>Mater Sci Eng C Mater Biol Appl</source><year>2016</year><volume>59</volume><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2015.09.056</pub-id><pub-id pub-id-type="pmid">26652359</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sivaraman B, Sylvester A, Ramamurthi A (2016) Fibrinolytic PLGA nanoparticles for slow clot lysis within abdominal aortic aneurysms attenuate proteolytic loss of vascular elastic matrix. Mater Sci Eng C Mater Biol Appl 59:145&#x02013;156. 10.1016/j.msec.2015.09.056<pub-id pub-id-type="pmid">26652359</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>WN</given-names></name><name><surname>L&#x000fc;</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>HB</given-names></name><etal/></person-group><article-title>Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel</article-title><source>Tissue Eng Part A</source><year>2009</year><volume>15</volume><issue>6</issue><fpage>1437</fpage><lpage>1447</lpage><pub-id pub-id-type="doi">10.1089/ten.tea.2008.0143</pub-id><pub-id pub-id-type="pmid">19061432</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Lu WN, L&#x000fc; SH, Wang HB et al (2009) Functional improvement of infarcted heart by co-injection of embryonic stem cells with temperature-responsive chitosan hydrogel. Tissue Eng Part A 15(6):1437&#x02013;1447. 10.1089/ten.tea.2008.0143<pub-id pub-id-type="pmid">19061432</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MM</given-names></name><name><surname>Carlini</surname><given-names>AS</given-names></name><name><surname>Chien</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction</article-title><source>Adv Mater</source><year>2015</year><volume>27</volume><issue>37</issue><fpage>5547</fpage><lpage>5552</lpage><pub-id pub-id-type="doi">10.1002/adma.201502003</pub-id><pub-id pub-id-type="pmid">26305446</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Nguyen MM, Carlini AS, Chien MP et al (2015) Enzyme-responsive nanoparticles for targeted accumulation and prolonged retention in heart tissue after myocardial infarction. Adv Mater 27(37):5547&#x02013;5552. 10.1002/adma.201502003<pub-id pub-id-type="pmid">26305446</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><etal/></person-group><article-title>Chitosan modification and pharmaceutical/biomedical applications</article-title><source>Mar Drugs</source><year>2010</year><volume>8</volume><issue>7</issue><fpage>1962</fpage><lpage>1987</lpage><pub-id pub-id-type="doi">10.3390/md8071962</pub-id><pub-id pub-id-type="pmid">20714418</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Zhang J, Xia W, Liu P et al (2010) Chitosan modification and pharmaceutical/biomedical applications. Mar Drugs 8(7):1962&#x02013;1987. 10.3390/md8071962<pub-id pub-id-type="pmid">20714418</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name></person-group><article-title>Targeted thrombolysis by using c-RGD-modified N, N, N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase</article-title><source>Drug Dev Ind Pharm</source><year>2019</year><volume>45</volume><issue>1</issue><fpage>88</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1080/03639045.2018.1522324</pub-id><pub-id pub-id-type="pmid">30198790</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Liao J, Ren X, Yang B, Li H, Zhang Y, Yin Z (2019) Targeted thrombolysis by using c-RGD-modified N, N, N-Trimethyl Chitosan nanoparticles loaded with lumbrokinase. Drug Dev Ind Pharm 45(1):88&#x02013;95. 10.1080/03639045.2018.1522324<pub-id pub-id-type="pmid">30198790</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><etal/></person-group><article-title>Tissue plasminogen activator-porous magnetic microrods for targeted thrombolytic therapy after ischemic stroke</article-title><source>ACS Appl Mater Interfaces</source><year>2018</year><volume>10</volume><issue>39</issue><fpage>32988</fpage><lpage>32997</lpage><pub-id pub-id-type="doi">10.1021/acsami.8b09423</pub-id><pub-id pub-id-type="pmid">30192506</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Hu J, Huang S, Zhu L et al (2018) Tissue plasminogen activator-porous magnetic microrods for targeted thrombolytic therapy after ischemic stroke. ACS Appl Mater Interfaces 10(39):32988&#x02013;32997. 10.1021/acsami.8b09423<pub-id pub-id-type="pmid">30192506</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="other">Galagudza M, Korolev, Postnov, et al. Passive targeting of ischemic-reperfused myocardium with adenosine-loaded silica nanoparticles.&#x000a0;Int J Nanomedicine. Published online 2012:1671. 10.2147/ijn.s29511</mixed-citation></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Mandhata</surname><given-names>CP</given-names></name><name><surname>Sahoo</surname><given-names>CR</given-names></name><name><surname>Padhy</surname><given-names>RN</given-names></name></person-group><article-title>Biomedical applications of biosynthesized gold nanoparticles from Cyanobacteria: an overview</article-title><source>Biol Trace Elem Res</source><year>2022</year><volume>200</volume><issue>12</issue><fpage>5307</fpage><lpage>5327</lpage><pub-id pub-id-type="doi">10.1007/s12011-021-03078-2</pub-id><pub-id pub-id-type="pmid">35083708</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Mandhata CP, Sahoo CR, Padhy RN (2022) Biomedical applications of biosynthesized gold nanoparticles from Cyanobacteria: an overview. Biol Trace Elem Res 200(12):5307&#x02013;5327. 10.1007/s12011-021-03078-2<pub-id pub-id-type="pmid">35083708</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DE</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Schellingerhout</surname><given-names>D</given-names></name><etal/></person-group><article-title>Quantitative imaging of cerebral thromboemboli in vivo: the effects of tissue-type plasminogen activator</article-title><source>Stroke</source><year>2017</year><volume>48</volume><issue>5</issue><fpage>1376</fpage><lpage>1385</lpage><pub-id pub-id-type="doi">10.1161/strokeaha.117.016511</pub-id><pub-id pub-id-type="pmid">28432262</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Kim DE, Kim JY, Schellingerhout D et al (2017) Quantitative imaging of cerebral thromboemboli in vivo: the effects of tissue-type plasminogen activator. Stroke 48(5):1376&#x02013;1385. 10.1161/strokeaha.117.016511<pub-id pub-id-type="pmid">28432262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Stankovich</surname><given-names>S</given-names></name><name><surname>Dikin</surname><given-names>DA</given-names></name><name><surname>Dommett</surname><given-names>GHB</given-names></name><etal/></person-group><article-title>Graphene-based composite materials</article-title><source>Nature</source><year>2006</year><volume>442</volume><issue>7100</issue><fpage>282</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1038/nature04969</pub-id><pub-id pub-id-type="pmid">16855586</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Stankovich S, Dikin DA, Dommett GHB et al (2006) Graphene-based composite materials. Nature 442(7100):282&#x02013;286. 10.1038/nature04969<pub-id pub-id-type="pmid">16855586</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Welsher</surname><given-names>K</given-names></name><etal/></person-group><article-title>Nano-graphene oxide for cellular imaging and drug delivery</article-title><source>Nano Res</source><year>2008</year><volume>1</volume><issue>3</issue><fpage>203</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1007/s12274-008-8021-8</pub-id><pub-id pub-id-type="pmid">20216934</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Sun X, Liu Z, Welsher K et al (2008) Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 1(3):203&#x02013;212. 10.1007/s12274-008-8021-8<pub-id pub-id-type="pmid">20216934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Sidorov</surname><given-names>IA</given-names></name><name><surname>Prabakaran</surname><given-names>P</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name></person-group><article-title>Non-covalent conjugation of nanoparticles to antibodies via electrostatic interactions&#x02014;a computational model</article-title><source>J Comput Theor Nanosci</source><year>2007</year><volume>4</volume><issue>6</issue><fpage>1103</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1166/jctn.2007.2385</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Sidorov IA, Prabakaran P, Dimitrov DS (2007) Non-covalent conjugation of nanoparticles to antibodies via electrostatic interactions&#x02014;a computational model. J Comput Theor Nanosci 4(6):1103&#x02013;1107. 10.1166/jctn.2007.2385</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>R</given-names></name><name><surname>Yuhi</surname><given-names>T</given-names></name><name><surname>Nagatani</surname><given-names>N</given-names></name><etal/></person-group><article-title>A novel enhancement assay for immunochromatographic test strips using gold nanoparticles</article-title><source>Anal Bioanal Chem</source><year>2006</year><volume>385</volume><issue>8</issue><fpage>1414</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1007/s00216-006-0549-4</pub-id><pub-id pub-id-type="pmid">16838160</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Tanaka R, Yuhi T, Nagatani N et al (2006) A novel enhancement assay for immunochromatographic test strips using gold nanoparticles. Anal Bioanal Chem 385(8):1414&#x02013;1420. 10.1007/s00216-006-0549-4<pub-id pub-id-type="pmid">16838160</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Morales</surname><given-names>J</given-names></name><name><surname>Fern&#x000e1;ndez-Penas</surname><given-names>R</given-names></name><name><surname>Acebedo-Mart&#x000ed;nez</surname><given-names>FJ</given-names></name><etal/></person-group><article-title>Luminescent citrate-functionalized terbium-substituted carbonated apatite nanomaterials: structural aspects, sensitized luminescence, cytocompatibility, and cell uptake imaging</article-title><source>Nanomaterials (Basel)</source><year>2022</year><volume>12</volume><issue>8</issue><fpage>1257</fpage><pub-id pub-id-type="doi">10.3390/nano12081257</pub-id><pub-id pub-id-type="pmid">35457965</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">G&#x000f3;mez-Morales J, Fern&#x000e1;ndez-Penas R, Acebedo-Mart&#x000ed;nez FJ et al (2022) Luminescent citrate-functionalized terbium-substituted carbonated apatite nanomaterials: structural aspects, sensitized luminescence, cytocompatibility, and cell uptake imaging. Nanomaterials (Basel) 12(8):1257. 10.3390/nano12081257<pub-id pub-id-type="pmid">35457965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Walkey</surname><given-names>CD</given-names></name><name><surname>Olsen</surname><given-names>JB</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Emili</surname><given-names>A</given-names></name><name><surname>Chan</surname><given-names>WCW</given-names></name></person-group><article-title>Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake</article-title><source>J Am Chem Soc</source><year>2012</year><volume>134</volume><issue>4</issue><fpage>2139</fpage><lpage>2147</lpage><pub-id pub-id-type="doi">10.1021/ja2084338</pub-id><pub-id pub-id-type="pmid">22191645</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Walkey CD, Olsen JB, Guo H, Emili A, Chan WCW (2012) Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J Am Chem Soc 134(4):2139&#x02013;2147. 10.1021/ja2084338<pub-id pub-id-type="pmid">22191645</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Sperling</surname><given-names>RA</given-names></name><name><surname>Parak</surname><given-names>WJ</given-names></name></person-group><article-title>Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles</article-title><source>Philos Trans A Math Phys Eng Sci</source><year>1915</year><volume>2010</volume><issue>368</issue><fpage>1333</fpage><lpage>1383</lpage><pub-id pub-id-type="doi">10.1098/rsta.2009.0273</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Sperling RA, Parak WJ (1915) Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philos Trans A Math Phys Eng Sci 2010(368):1333&#x02013;1383. 10.1098/rsta.2009.0273</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>J</given-names></name><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Iida</surname><given-names>M</given-names></name><etal/></person-group><article-title>An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy</article-title><source>Nano Lett</source><year>2020</year><volume>20</volume><issue>7</issue><fpage>4901</fpage><lpage>4909</lpage><pub-id pub-id-type="doi">10.1021/acs.nanolett.0c00953</pub-id><pub-id pub-id-type="pmid">32510959</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Bu J, Nair A, Iida M et al (2020) An avidity-based PD-L1 antagonist using nanoparticle-antibody conjugates for enhanced immunotherapy. Nano Lett 20(7):4901&#x02013;4909. 10.1021/acs.nanolett.0c00953<pub-id pub-id-type="pmid">32510959</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Mao</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Surface spermidine functionalized PEGylated poly(lactide-co-glycolide) nanoparticles for tumor-targeted drug delivery</article-title><source>RSC Adv</source><year>2017</year><volume>7</volume><issue>37</issue><fpage>22954</fpage><lpage>22963</lpage><pub-id pub-id-type="doi">10.1039/c7ra02447a</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Li J, Mao J, Tang J et al (2017) Surface spermidine functionalized PEGylated poly(lactide-co-glycolide) nanoparticles for tumor-targeted drug delivery. RSC Adv 7(37):22954&#x02013;22963. 10.1039/c7ra02447a</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>WL</given-names></name><name><surname>O&#x02019;Shannessy</surname><given-names>DJ</given-names></name></person-group><article-title>Site-specific immobilization of antibodies by their oligosaccharide moieties to new hydrazide derivatized solid supports</article-title><source>J Immunol Methods</source><year>1988</year><volume>112</volume><issue>1</issue><fpage>113</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/0022-1759(88)90041-5</pub-id><pub-id pub-id-type="pmid">2457052</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Hoffman WL, O&#x02019;Shannessy DJ (1988) Site-specific immobilization of antibodies by their oligosaccharide moieties to new hydrazide derivatized solid supports. J Immunol Methods 112(1):113&#x02013;120. 10.1016/0022-1759(88)90041-5<pub-id pub-id-type="pmid">2457052</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Kantner</surname><given-names>T</given-names></name><name><surname>Watts</surname><given-names>AG</given-names></name></person-group><article-title>Characterization of reactions between water-soluble trialkylphosphines and thiol alkylating reagents: implications for protein-conjugation reactions</article-title><source>Bioconjug Chem</source><year>2016</year><volume>27</volume><issue>10</issue><fpage>2400</fpage><lpage>2406</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.6b00375</pub-id><pub-id pub-id-type="pmid">27602944</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Kantner T, Watts AG (2016) Characterization of reactions between water-soluble trialkylphosphines and thiol alkylating reagents: implications for protein-conjugation reactions. Bioconjug Chem 27(10):2400&#x02013;2406. 10.1021/acs.bioconjchem.6b00375<pub-id pub-id-type="pmid">27602944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Akkapeddi</surname><given-names>P</given-names></name><name><surname>Azizi</surname><given-names>SA</given-names></name><name><surname>Freedy</surname><given-names>AM</given-names></name><name><surname>Cal</surname><given-names>PMSD</given-names></name><name><surname>Gois</surname><given-names>PMP</given-names></name><name><surname>Bernardes</surname><given-names>GJL</given-names></name></person-group><article-title>Construction of homogeneous antibody&#x02013;drug conjugates using site-selective protein chemistry</article-title><source>Chem Sci</source><year>2016</year><volume>7</volume><issue>5</issue><fpage>2954</fpage><lpage>2963</lpage><pub-id pub-id-type="doi">10.1039/c6sc00170j</pub-id><pub-id pub-id-type="pmid">29997785</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Akkapeddi P, Azizi SA, Freedy AM, Cal PMSD, Gois PMP, Bernardes GJL (2016) Construction of homogeneous antibody&#x02013;drug conjugates using site-selective protein chemistry. Chem Sci 7(5):2954&#x02013;2963. 10.1039/c6sc00170j<pub-id pub-id-type="pmid">29997785</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Renault</surname><given-names>K</given-names></name><name><surname>Fredy</surname><given-names>JW</given-names></name><name><surname>Renard</surname><given-names>PY</given-names></name><name><surname>Sabot</surname><given-names>C</given-names></name></person-group><article-title>Covalent modification of biomolecules through maleimide-based labeling strategies</article-title><source>Bioconjug Chem</source><year>2018</year><volume>29</volume><issue>8</issue><fpage>2497</fpage><lpage>2513</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.8b00252</pub-id><pub-id pub-id-type="pmid">29954169</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Renault K, Fredy JW, Renard PY, Sabot C (2018) Covalent modification of biomolecules through maleimide-based labeling strategies. Bioconjug Chem 29(8):2497&#x02013;2513. 10.1021/acs.bioconjchem.8b00252<pub-id pub-id-type="pmid">29954169</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Herr</surname><given-names>AE</given-names></name></person-group><article-title>Protein immobilization techniques for microfluidic assays</article-title><source>Biomicrofluidics.</source><year>2013</year><volume>7</volume><issue>4</issue><fpage>041507</fpage><pub-id pub-id-type="doi">10.1063/1.4816934</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Kim D, Herr AE (2013) Protein immobilization techniques for microfluidic assays. Biomicrofluidics. 7(4):041507. 10.1063/1.4816934</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Kirpotin</surname><given-names>D</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Hong</surname><given-names>K</given-names></name><etal/></person-group><article-title>Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells <italic>in vitro</italic></article-title><source>Biochemistry</source><year>1997</year><volume>36</volume><issue>1</issue><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1021/bi962148u</pub-id><pub-id pub-id-type="pmid">8993319</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Kirpotin D, Park JW, Hong K et al (1997) Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells <italic>in vitro</italic>. Biochemistry 36(1):66&#x02013;75. 10.1021/bi962148u<pub-id pub-id-type="pmid">8993319</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Rommasi</surname><given-names>F</given-names></name><name><surname>Esfandiari</surname><given-names>N</given-names></name></person-group><article-title>Liposomal nanomedicine: applications for drug delivery in cancer therapy</article-title><source>Nanoscale Res Lett.</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>95</fpage><pub-id pub-id-type="doi">10.1186/s11671-021-03553-8</pub-id><pub-id pub-id-type="pmid">34032937</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Rommasi F, Esfandiari N (2021) Liposomal nanomedicine: applications for drug delivery in cancer therapy. Nanoscale Res Lett. 16(1):95. 10.1186/s11671-021-03553-8<pub-id pub-id-type="pmid">34032937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Miyoshi</surname><given-names>H</given-names></name><name><surname>Nakamura</surname><given-names>M</given-names></name></person-group><article-title>Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles</article-title><source>Int J Cancer</source><year>2007</year><volume>120</volume><issue>12</issue><fpage>2527</fpage><lpage>2537</lpage><pub-id pub-id-type="doi">10.1002/ijc.22709</pub-id><pub-id pub-id-type="pmid">17390371</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Liu Y, Miyoshi H, Nakamura M (2007) Nanomedicine for drug delivery and imaging: a promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120(12):2527&#x02013;2537. 10.1002/ijc.22709<pub-id pub-id-type="pmid">17390371</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Hein</surname><given-names>CD</given-names></name><name><surname>Liu</surname><given-names>XM</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name></person-group><article-title>Click chemistry, a powerful tool for pharmaceutical sciences</article-title><source>Pharm Res</source><year>2008</year><volume>25</volume><issue>10</issue><fpage>2216</fpage><lpage>2230</lpage><pub-id pub-id-type="doi">10.1007/s11095-008-9616-1</pub-id><pub-id pub-id-type="pmid">18509602</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Hein CD, Liu XM, Wang D (2008) Click chemistry, a powerful tool for pharmaceutical sciences. Pharm Res 25(10):2216&#x02013;2230. 10.1007/s11095-008-9616-1<pub-id pub-id-type="pmid">18509602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Said Hassane</surname><given-names>F</given-names></name><name><surname>Frisch</surname><given-names>B</given-names></name><name><surname>Schuber</surname><given-names>F</given-names></name></person-group><article-title>Targeted liposomes: convenient coupling of ligands to preformed vesicles using &#x0201c;click chemistry&#x0201d;</article-title><source>Bioconjug Chem</source><year>2006</year><volume>17</volume><issue>3</issue><fpage>849</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.1021/bc050308l</pub-id><pub-id pub-id-type="pmid">16704226</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Said Hassane F, Frisch B, Schuber F (2006) Targeted liposomes: convenient coupling of ligands to preformed vesicles using &#x0201c;click chemistry.&#x0201d; Bioconjug Chem 17(3):849&#x02013;854. 10.1021/bc050308l<pub-id pub-id-type="pmid">16704226</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Chivers</surname><given-names>CE</given-names></name><name><surname>Koner</surname><given-names>AL</given-names></name><name><surname>Lowe</surname><given-names>ED</given-names></name><name><surname>Howarth</surname><given-names>M</given-names></name></person-group><article-title>How the biotin&#x02013;streptavidin interaction was made even stronger: investigation via crystallography and a chimaeric tetramer</article-title><source>Biochem J</source><year>2011</year><volume>435</volume><issue>1</issue><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1042/bj20101593</pub-id><pub-id pub-id-type="pmid">21241253</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Chivers CE, Koner AL, Lowe ED, Howarth M (2011) How the biotin&#x02013;streptavidin interaction was made even stronger: investigation via crystallography and a chimaeric tetramer. Biochem J 435(1):55&#x02013;63. 10.1042/bj20101593<pub-id pub-id-type="pmid">21241253</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname><given-names>E</given-names></name><name><surname>Willner</surname><given-names>I</given-names></name></person-group><article-title>Integrated nanoparticle-biomolecule hybrid systems: synthesis, properties, and applications</article-title><source>Angew Chem Int Ed Engl</source><year>2004</year><volume>43</volume><issue>45</issue><fpage>6042</fpage><lpage>6108</lpage><pub-id pub-id-type="doi">10.1002/anie.200400651</pub-id><pub-id pub-id-type="pmid">15538757</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Katz E, Willner I (2004) Integrated nanoparticle-biomolecule hybrid systems: synthesis, properties, and applications. Angew Chem Int Ed Engl 43(45):6042&#x02013;6108. 10.1002/anie.200400651<pub-id pub-id-type="pmid">15538757</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>JD</given-names></name><name><surname>Eslamizar</surname><given-names>L</given-names></name><name><surname>Filanoski</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation</article-title><source>Anal Biochem</source><year>2002</year><volume>308</volume><issue>2</issue><fpage>343</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/s0003-2697(02)00201-4</pub-id><pub-id pub-id-type="pmid">12419349</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Hirsch JD, Eslamizar L, Filanoski BJ et al (2002) Easily reversible desthiobiotin binding to streptavidin, avidin, and other biotin-binding proteins: uses for protein labeling, detection, and isolation. Anal Biochem 308(2):343&#x02013;357. 10.1016/s0003-2697(02)00201-4<pub-id pub-id-type="pmid">12419349</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Marttila</surname><given-names>AT</given-names></name><name><surname>Hyt&#x000f6;nen</surname><given-names>VP</given-names></name><name><surname>Laitinen</surname><given-names>OH</given-names></name><name><surname>Bayer</surname><given-names>EA</given-names></name><name><surname>Wilchek</surname><given-names>M</given-names></name><name><surname>Kulomaa</surname><given-names>MS</given-names></name></person-group><article-title>Mutation of the important Tyr-33 residue of chicken avidin: functional and structural consequences</article-title><source>Biochem J</source><year>2003</year><volume>369</volume><issue>2</issue><fpage>249</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1042/bj20020886</pub-id><pub-id pub-id-type="pmid">12358604</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Marttila AT, Hyt&#x000f6;nen VP, Laitinen OH, Bayer EA, Wilchek M, Kulomaa MS (2003) Mutation of the important Tyr-33 residue of chicken avidin: functional and structural consequences. Biochem J 369(2):249&#x02013;254. 10.1042/bj20020886<pub-id pub-id-type="pmid">12358604</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Conde</surname><given-names>J</given-names></name><name><surname>Dias</surname><given-names>JT</given-names></name><name><surname>Graz&#x000c3;o</surname><given-names>V</given-names></name><name><surname>Moros</surname><given-names>M</given-names></name><name><surname>Baptista</surname><given-names>PV</given-names></name><name><surname>de la Fuente</surname><given-names>JM</given-names></name></person-group><article-title>Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine</article-title><source>Front Chem</source><year>2014</year><volume>2</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.3389/fchem.2014.00048</pub-id><pub-id pub-id-type="pmid">25077142</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Conde J, Dias JT, Graz&#x000c3;o V, Moros M, Baptista PV, de la Fuente JM (2014) Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front Chem 2:48. 10.3389/fchem.2014.00048<pub-id pub-id-type="pmid">25077142</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>